Endomyocardial fibrosis: recent advances and future therapeutic targets.

Summary: Imagine a condition that slowly turns the heart’s flexible inner lining into stiff scar tissue, preventing it from pumping effectively. This is Endomyocardial Fibrosis (EMF), a mysterious and often devastating heart disease that primarily strikes children and adolescents in tropical regions of Africa, Asia, and South America. Despite being identified over 75 years ago, doctors still don't know exactly what triggers it. While current heart failure medications and specialized surgeries have improved survival rates slightly, the long-term outlook for these young patients remains poor. Today, researchers are urgently hunting for "biomarkers"—early warning signs in the blood—and new therapies to stop the scarring before the damage becomes irreversible.